Tıp Fakültesi / Faculty of Medicine

Permanent URI for this collectionhttps://hdl.handle.net/11727/1403

Browse

Filters

2015 - 2019292020 - 20235

Settings

Author: search.filters.author.Yildirim, Berna Akkussearch.filters.applied.f.rights: search.filters.rights.info:eu-repo/semantics/closedAccess

Search Results

Now showing 1 - 10 of 34
  • No Thumbnail Available
    Item
    Safety and Palliative Efficacy of Single-Dose 8-Gy Reirradiation for Painful Local Failure in Patients with Stage IV Non-Small Cell Lung Cancer Previously Treated with Radical Chemoradiation Therapy
    (2015) Topkan, Erkan; Yildirim, Berna Akkus; Guler, Ozan Cem; Parlak, Cem; Pehlivan, Berrin; Selek, Ugur; 0000-0001-8120-7123; 0000-0001-6170-0383; 0000-0001-6661-4185; 0000-0001-6908-3412; 0000-0001-8087-3140; 25752391; AAG-2213-2021; B-3671-2014; V-5717-2017; AAC-5654-2020; O-5474-2014
    Purpose: To investigate the safety and efficacy of single-dose 8-Gy palliative chest reirradiation (CRI) in metastatic non-small cell lung cancer (M-NSCLC) patients with painful thoracic failures (TF) within the previous radiation portal. Patients and Methods: We retrospectively analyzed the clinical data of 78 M-NSCLC patients who received single-dose 8-Gy CRI for painful TF after concurrent chemoradiation therapy to a total radiation dose of 52 to 66 Gy between 2007 and 2012. Primary endpoints included significant pain relief (SPR) defined as a >= 2 point decrement in the Visual Analogue Scale for Pain inventory (VAS-P), time to pain relief, and duration of pain control. Secondary objectives were survival and prognostic factors. Results: Treatment was well tolerated, with only 5.1% grade 3 pneumonitis and 1.3% grade 2 esophagitis. Pre-CRI median and post-CRI minimum VAS-P were 7 and 3 (P < .001), respectively. SPR was noted in 67 (85.9%) patients, and only 3 (3.9%) scored progressive pain. Median time to lowest VAS-P and duration of pain control were 27 days and 6.1 months, respectively. Median overall survival (OS) was 7.7 months, and the 1-year OS rate was 26.5%. On multivariate analyses, lower Eastern Cooperative Oncology group score (1-2; P < .001), absence of anemia (P = .001), and fewer metastatic sites (1-2; P < .001) were found to be associated with longer OS. Conclusions: Single-dose 8-Gy CRI provides safe, effective, and durable pain palliation for TF in radically irradiated M-NSCLC patients. Because of its convenience, lower cost, and higher comfort, the present protocol can be considered an appropriate option for patients with limited life spans. (C) 2015 Elsevier Inc.
  • No Thumbnail Available
    Item
    Prevention of Radiation-Induced Retinopathy with Amifostine in Wistar Albino Rats
    (2015) Yildirim, Berna Akkus; Cetin, Eren; Topkan, Erkan; Ozyigit, Gokhan; Cengiz, Mustafa; Surucu, Selcuk; Usubutun, Alp; Akyol, Fadil; 0000-0001-6661-4185; 25768249; V-5717-2017
  • No Thumbnail Available
    Item
    Untitled Reply
    (2015) Yildirim, Berna Akkus; Topkan, Erkan; 0000-0001-8120-7123; 0000-0001-6661-4185; 26502011; AAG-2213-2021; V-5717-2017
  • No Thumbnail Available
    Item
    Prognosis of Stage III NSCLC Patients Presenting with Isolated Brain Failure after Definitive Concurrent Chemoradiotherapy
    (2015) Topkan, Erkan; Yildirim, Berna Akkus; Guler, Ozanc; Ozdemir, Yurday; 0000-0001-8120-7123; 0000-0002-2218-2074; 0000-0001-6661-4185; AAG-2213-2021; AAG-5629-2021; V-5717-2017
  • No Thumbnail Available
    Item
    Elective Nodal Irradiation Does Not Alter Isolated Nodal Failure and Survival Outcomes in Stage III NSCLC Patients Undergoing Chemoradiotherapy
    (2015) Topkan, Erkan; Yildirim, Berna Akkus; Guler, Ozanc; Ozdemir, Yurday; 0000-0002-2218-2074; 0000-0001-8120-7123; 0000-0001-6661-4185; AAG-5629-2021; AAG-2213-2021; V-5717-2017
  • No Thumbnail Available
    Item
    Survival Analysis of 51 Leptomeningeal Metastatic Non Small Cell Lung Cancer Patients Treated with Whole Brain Radiotherapy
    (2015) Topkan, Erkan; Yildirim, Berna Akkus; Guler, Ozan C.; Ozdemir, Yurday; 0000-0001-6908-3412; 0000-0001-8120-7123; 0000-0001-6661-4185; 0000-0002-2218-2074; AAC-5654-2020; AAG-2213-2021; V-5717-2017; AAG-5629-2021
  • No Thumbnail Available
    Item
    Weight Loss before Radical Chemoradiotherapy Is Associated with Poorer Survival Outcomes in Overweight Locally Advanced NSCLC Patients
    (2015) Topkan, Erkan; Yildirim, Berna Akkus; Ozdemir, Yurday; Guler, Ozan C.; Ozyilkan, Ozgur; 0000-0001-6661-4185; 0000-0002-2218-2074; 0000-0001-8825-4918; 0000-0001-8120-7123; 0000-0001-6908-3412; V-5717-2017; AAG-5629-2021; AAD-2817-2021; AAG-2213-2021; AAC-5654-2020
  • No Thumbnail Available
    Item
    Effective Resolution of Lung Cancer Related Tracheal and/or Bronchial Obstruction with External Beam Radiotherapy
    (2015) Topkan, Erkan; Yildirim, Berna Akkus; Ozdemir, Yurday; Guler, Ozan C.; Kose, Fatih; 0000-0001-6908-3412; 0000-0001-8120-7123; 0000-0002-2218-2074; 0000-0001-6661-4185; AAC-5654-2020; AAG-2213-2021; AAG-5629-2021; V-5717-2017
  • No Thumbnail Available
    Item
    Factors Associated with Brain Metastasis Development in Radically Treated Stage IIIB Non-Small Cell Lung Cancer Patients
    (2015) Topkan, Erkan; Yildirim, Berna Akkus; Guler, Ozan C.; Ozdemir, Yurday; 0000-0001-6908-3412; 0000-0001-6661-4185; 0000-0001-8120-7123; 0000-0002-2218-2074; AAC-5654-2020; V-5717-2017; AAG-2213-2021; AAG-5629-2021
  • No Thumbnail Available
    Item
    Retrospective Comparison of Standard and Escalated Doses of Radiotherapy in Newly Diagnosed Glioblastoma Patients Treated with Concurrent and Adjuvant Temozolomide
    (2019) Guler, Ozan Cem; Yildirim, Berna Akkus; Onal, Cem; Topkan, Erkan; https://orcid.org/0000-0001-6908-3412; https://orcid.org/0000-0001-6661-4185; https://orcid.org/0000-0002-2742-9021; https://orcid.org/0000-0001-8120-7123; 30950447; AAC-5654-2020; V-5717-2017; HOC-5611-2023; AAG-2213-2021
    BACKGROUND: To compare the efficacies of standard dose-(SDRT) and escalated dose radiotherapy (EDRT) in newly diagnosed glioblastoma (GBM) with concurrent and adjuvant temozolomide (TMZ). MATERIALS AND METHODS: Outcomes of 126 newly diagnosed GBM patients who received SDRT (60 Gy, 30 fractions) or EDRT (70 Gy, 30 fractions) with concurrent plus adjuvant TMZ were retrospectively analyzed. Both groups received concurrent TMZ (75 mg/m(2)) during the course of RT and at least one course of adjuvant TMZ (150-200 mg/m(2)), thereafter. Overall survival (OS) and local progression free survival (LPFS) constituted the primary and secondary endpoints, respectively. RESULTS: At median 14.2 months follow-up, 26 (20.6%) patients were alive. Median LPFS and OS were 9.2 [95% confidence interval (CI); 8.4-10.0] and 15.4 months (95% CI; 12.1-18.8), respectively, for the entire cohort. Although the median OS was numerically superior in the EDRT this difference could not reach statistical significance (22.0 vs. 14.9 months; P = 0.45), Likewise, LPFS was also (9.9 vs. 8.9 months; P = 0.89) not different between the two treatment groups. In multivariate analysis, better recursive partitioning analysis class (3-4 vs. 5; P = 0.044) and extensive surgery (gross total resection vs. subtotal resection/biopsy only; P = 0.021) were identified to associate significantly with superior OS times, irrespective of the RT protocol. CONCLUSIONS: Although the current median OS of 22 months of the EDRT group is promising, no statistically significant survival advantage for EDRT was observed even in the presence of TMZ. Randomized studies with larger population sizes and available genetic markers are warranted to conclude more reliably on the fate of EDRT plus TMZ.